Abstract:8527 Background: KIT is an important oncogene in acral and mucosal melanomas, which account for 70% of melanomas in Asian patients (Pts). We conducted a phase II study (NCT00881049) to test the KIT inhibitor imatinib in metastatic melanoma pts with KIT aberrations. Methods: Pts with metastatic or unresectable melanoma whose tumor had KIT aberrations (KIT mutation [mut] and/or KIT gene DNA amplification [amp]) and who had measurable disease were enrolled. Pts received imatinib 400 mg/d continually until disease progression or intolerable toxicity. The dosage of Imatinib was escalated to 600 mg or 800 mg per day if progression was observed. Response was assessed monthly using RECIST criteria. The endpoints were progression-free survival (PFS), overall response rate (ORR) and toxicity. Results: Of 390 cases screened, 67 (17.4%) had a KIT mut or amp: 26/137 (18.9%) acral, 21/110 (19.1%) mucosal, 9/26 (34.6%) CSD, 6/75 (8%) NCSD, 5/42 (11.9%) unknown primary. 41 (10.5%) had a mut only; 23 (5.9%) had an amp only; 3 (0.8%) had both. Thus far, 28 patients have been treated with 26 pts currently evaluable: 5 stage M1a/3 M1b/20 M1c; median prior therapies: 2. Six patients (21%) achieved PR (5 mut, 1 amp, 4∼10+m); nine patients (35%) received SD (≥ 3 m, 3.5∼9+m). Pts who failed on 400mg also failed on escalation to 600mg and could not tolerate 800mg due to toxicities. Samples of new or progressive lesions were obtained from 5 PR pts after they failed on imatinib 400mg, and were analyzed in KIT, BRAF and PDGFRA. In one pt (emerging metastasis in liver) new mutations were found in BRAF (V600E) and PDGFRA (W559stop) which were wild-type before treatment, and loss of the KIT mutation present at baseline. Common toxicities at 400 mg were rash, vomiting, edema and myelosuppresion. Conclusions: Imatinib (400mg/d) provides a beneficial therapeutic effect for a significant proportion of Chinese metastatic melanoma pts with KIT aberrations. Acquired genetic mutations after treatment may account for emergence of resistance in some pts. Supported by the National Natural Science Foundation of China (30973483), 985-2-085-113 and Novartis Oncology in China. No significant financial relationships to disclose.

[Secondary Mutation of C-Kit/pdgfrα Genotypes after Imatinib Mesylate Therapy and Its Relationship with Efficacy of Sunitinib].

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

Secondary Mutations of C-Kit Contribute to Acquired Resistance to Imatinib and Decrease Efficacy of Sunitinib in Chinese Patients with Gastrointestinal Stromal Tumors

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Followed by Sunitinib Compared to Followed by Imatinib-a Multi-Center Cohort Study

Secondary Resistance to Imatinib in Patients with Gastrointestinal Stromal Tumors Through an Acquired KIT Exon 17 Mutation.

C-KIT Mutations Were Closely Associated with the Response to Imatinib in Chinese Advanced Gastrointestinal Stromal Tumor Patients.

Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors

[Study on the Mechanism of Imatinib-Induced Resistance in Gastrointestinal Stromal Tumors].

Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.

Preclinical model-based evaluation of Imatinib resistance induced by <i>KIT</i> mutations and its overcoming strategies in gastrointestinal stromal tumor (GIST)

Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review

Preclinical model-based evaluation of Imatinib resistance induced by KIT mutations and its overcoming strategies in gastrointestinal stromal tumor (GIST)

Oncogenic Signaling Mechanisms in Imatinib-Resistant Gastrointestinal Stromal Tumor

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours

The Genetic and Immunohistochemical Characteristics in Imatinib-Resistant Gastrointestinal Stromal Tumor

Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

A Phase Ii Study of Imatinib for Advanced Melanoma Patients with Kit Aberrations

Clinical Outcomes of Imatinib Dose Escalation Versus Sunitinib in First-Line Imatinib-Failure Gastrointestinal Stromal Tumour

Clinical Benefit of Sunitinib in Gastrointestinal Stromal Tumors with Different Exon 11 Mutation Genotypes

A study on the mutation and expression of c-kit and PDGFR-α gene in gastrointestinal stromal tumor

[Molecular Mechanism of Gastrointestinal Stromal Tumors and Progress in Drug Research].